Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: Differential effects of growth factor type and role of CD34+ cell dose

Bone Marrow Transplantation

Volumn 27, Issue 8, 2001, Pages 791-800

  Keever Taylor, C A ^a   Klein, J P ^a   Eastwood, D ^a   Bredeson, C ^a   Margolis, D A ^a   Burns, W H ^a   Vesole, D H ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Bone marrow transplantation; Engraftment kinetics; T cell depletion

Indexed keywords

CD3 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; METHYLPREDNISOLONE; OKT 3; THYMOCYTE ANTIBODY;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGE; ALLOGRAFT; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CELL KINETICS; CELL MATURATION; CHILD; CHRONIC LEUKEMIA; CONTROLLED STUDY; CYTOLYSIS; CYTOMEGALOVIRUS; DIAGNOSIS; FEMALE; GENDER; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INFANT; LYMPHOCYTE DEPLETION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPHIL; PRIORITY JOURNAL; RECIPIENT; REGRESSION ANALYSIS; SERODIAGNOSIS; T LYMPHOCYTE; THROMBOCYTE;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGENS, CD34; BLOOD DONORS; BLOOD PLATELETS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GRAFT SURVIVAL; GROWTH SUBSTANCES; HEMATOLOGIC DISEASES; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; NEUTROPHILS; RETROSPECTIVE STUDIES; RISK FACTORS; T-LYMPHOCYTES; TIME FACTORS;

EID: 0034991285     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702872     Document Type: Article

References (51)

1. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: Advantage of T-cell antibodies with narrow specificities
2. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia
3. Recombinant cytokines and hematopoietic growth factors in allogeneic and autologous bone marrow transplantation
4. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation
5. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation
6. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: Double-blind, placebo-controlled trial
7. Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation
8. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation
9. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis
10. Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation
11. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: A prospective, randomized trial
12. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: Results of a randomized BNLI trial
13. Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: Results of a prospective randomized trial
14. Peripheral blood stem cells (PBPCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation
15. Factors that influence collection and engraftment of autologous peripheral-blood stem cells
16. Primordial role of CD34+ 38-cells in early and late trilineage haemopoietic engraftment after autologous blood cell transplantation
17. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation
18. Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation
19. Successful allogeneic marrow transplantation from closely HLA-matched unrelated donors using T-cell depletion
20. Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults
21. Future directions in selection of donors for bone marrow transplantation: Role of oligonucleotide genotyping
22. Use of solid phase automated sequencing to define HLA disparity between bone marrow donors and recipients
23. HLA-B44-directed cytotoxic T cells associated with acute graft-versus-host disease following unrelated bone marrow transplantation
24. Sensitive detection and enumeration of CD34+ cells in peripheral and cord blood by flow cytometry
25. The ISHAGE guidelines for CD34+ cell determination by flow cytometry International Society of Hematotherapy and Graft Engineering
26. A new limiting dilution culture system for the detection of T cell subsets in T cell-depleted marrow grafts
27. Host origin of marrow stromal cells following allogeneic bone marrow transplantation
28. Graft failure following bone marrow transplantation for severe aplastic anemia: Risk factors and treatment results
29. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: A report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group
30. Graft-v-host disease is associated with autoimmune-like thrombocytopenia
31. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: A randomized study
32. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post autologous stem cell transplantation
33. Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation. A prospective randomized study
34. Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: A prospective randomized trial
35. Randomized comparison of two different schedules of granulocyte colony-stimulating factor administration after allogeneic bone marrow transplantation
36. Clinical use of hematopoietic growth factors in allogeneic bone marrow transplantation
37. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation
38. Granulocyte-colony-stimulating factor after allogeneic and autologous bone marrow transplantation in children
39. Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors
40. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia
41. Randomized study of growth factors post-peripheral-blood stem-cell transplant: Neutrophil recovery is improved with modest clinical benefit
42. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone for lymphoid malignancies
43. Hematopoietic growth factors for graft failure after bone marrow transplantation: A randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF
44. Myeloid colony-stimulating factors: Use in the newborn
45. Hematopoietic growth factor after autologous peripheral blood transplantation: Comparison of G-CSF and GM-CSF
46. Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells
47. Exclusive expression of G-CSF receptor on myeloid progenitors in bone marrow CD34+ cells
48. Granulocyte colony-stimulating factor (G-CSF) induces the production of cytokines in vivo
49. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor
50. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy
51. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy